Lupus Science & Medicine

Can disease activity and treatment responses be captured by a core set of domains in SLE clinical trials? An analysis of phase III belimumab trial data

Objective Outcome measures used in SLE randomised controlled trials (RCTs) have impeded trial success and drug approval. In ...
Lupus Science & Medicine

Incidence of serious infections, herpes zoster and hepatitis B virus reactivation among patients with SLE: a cohort study using a health claims database in Japan

Objectives To investigate the real-world incidence of serious infections (SI), herpes zoster (HZ) and hepatitis B virus (HBV) ...
lupus.bmj

Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial

Objective To characterise the safety and efficacy of anifrolumab in active lupus nephritis (LN) through year 2 of the phase II randomised, double-blind Treatment of Uncontrolled Lupus via the ...
lupus.bmj

Successful autologous CD19 CAR T cell therapy following severe lupus flare during immunosuppressive washout in refractory lupus nephritis

Objective To evaluate the safety and efficacy of CD19 chimeric antigen receptor (CAR) T cell therapy in a patient with refractory lupus nephritis who experienced severe disease flare during ...
lupus.bmj

Quinolinic acid, a kynurenine/tryptophan pathway metabolite, associates with impaired cognitive test performance in systemic lupus erythematosus

Objectives Interferon-alpha, an important contributor to SLE pathogenesis, induces the enzyme indoleamine 2,3-dioxygenase in the kynurenine/tryptophan (KYN/TRP) pathway. This leads to a potentially ...
lupus.bmj

Belimumab versus telitacicept in sequential treatment after rituximab for refractory lupus nephritis: a real-world multicentre study

Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been approved as add-on therapies for SLE in China. The aim of this study is to ...
lupus.bmj

PO:11:300 Evaluating DORIS remission attainment with anifrolumab in immunosuppressant- and biologic-naïve patients with SLE: design of SUNFLOWER, a phase 3b prospective study

Objectives DORIS remission is protective against organ damage in patients with SLE. 1 Treatment recommendations prioritize a treat-to-target approach aiming for prompt remission, including adding ...
lupus.bmj

Urinary markers differentially associate with kidney inflammatory activity and chronicity measures in patients with lupus nephritis

Objective Lupus nephritis (LN) is diagnosed by biopsy, but longitudinal monitoring assessment methods are needed. Here, in this preliminary and hypothesis-generating study, we evaluate the potential ...
lupus.bmj

NLR outperforms PLR in SLE diagnosis and prognosis: an AI-enhanced meta-analysis of 12 850 patients with ethnicity-specific cut-offs

Objectives To evaluate the diagnostic and prognostic performance of the neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) in SLE and to integrate these biomarkers into an ...
lupus.bmj

Proteomic analysis reveals angiogenesis-related plasma proteins associated with pre-eclampsia in SLE

Objective Delivery of a small for gestational age (SGA) infant is a common pregnancy complication among women with SLE. Although disease activity and autoantibodies such as anti-Smith and ...
lupus.bmj

PO:13:335 Real-world use of voclosporin in lupus nephritis

Objectives Following the successful AURORA-1 and AURORA-2 trials, voclosporin was incorporated into the KDIGO 2024 clinical guidelines for the management of active Class III or IV lupus nephritis, ...